Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anifrolumab for Vascular Risk in Systemic Lupus Erythematosus
NCT05440422Phase 2Recruiting
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- Start
- Dec 2023
- Primary completion
- Aug 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of anifrolumab in systemic lupus erythematosus (SLE), sponsored by National Institute of Arthritis and Musculoskeletal and Skin Diseases. Started Dec 2023; status: recruiting.
02
Drugs
anifrolumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT05440422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05440422.